ENYO Pharma ("ENYO"), a clinical-stage biopharmaceutical company developing innovative therapies for kidney diseases, today confirmed positive results from its Phase 2 Alpestria-1 study of vonafexor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback